Alzheimer Disease Clinical Trial
Official title:
The Role of Periodontitis and Periodontal Bacteria in Development of Dementia
The study is designed to inquire whether the presence of periodontitis and different periodontopathogenic bacterial strains are associated with dementia diagnosis and with the degree of cognitive impairment in participants evaluated at a Memory clinic (Minnesmottagning). Specifically, by analyzing cerebrospinal fluid, the investigators intend to clarify whether the alleged mechanisms for Porphyromonas gingivalis in the aetiology of Alzheimer disease (AD) are supported in a Swedish population and whether they are specific for Porphyromonas gingivalis (as compared to other periodontopathogenic bacteria) and Alzheimer type dementia (as compared to other etiological dementia types), respectively.
Purpose and aims The study is designed to inquire whether the presence of periodontitis and different periodontopathogenic bacterial strains are associated with dementia diagnosis and with the degree of cognitive impairment in patients evaluated at a Memory clinic (Minnesmottagning). Specifically, by analyzing cerebrospinal fluid (CSF) samples, the investigators intend to clarify whether the alleged mechanisms for Porphyromonas gingivalis (P. gingivalis) in the aetiology of AD are supported in a Swedish population and whether they are specific for P. gingivalis (as compared to other periodontopathogenic bacteria) and Alzheimer type dementia (as compared to other etiological dementia types), respectively. Research questions In what proportion of Swedish dementia cases is bacterial DNA from periodontal pathogens, antibodies against periodontal pathogens, gingipain protein from P. gingivalis and gingipain enzyme activity found in CSF? Are these bacteriological findings in the CSF more common or more elevated in individuals that received a diagnosis of dementia, as compared to individuals with a lower level of cognitive dysfunction (e.g. mild cognitive impairment, subjective cognitive impairment, or no diagnosis)? Are measurements of cognitive function, e.g. mini-mental state examination (MMSE) scores, correlated with bacteriological findings in the CSF, including gingipain activity? Is the prevalence of periodontitis higher in participants that received a diagnosis of dementia, as compared to participants with a lower level of cognitive dysfunction? Was the prevalence of periodontitis, 5 - 15 years prior to the diagnostic evaluation, higher in participants that received a diagnosis of dementia, as compared to participants with a lower level of cognitive dysfunction? Are measurements of cognitive function, e.g. mini-mental state examination (MMSE) scores, correlated with periodontitis-related findings? In that case, does the correlation depend on the time interval between the periodontal and the cognitive assessments? Are the above bacteriological findings in the CSF more common or more elevated in participants with severe periodontitis, as compared to participants with mild or no periodontitis? Are periodontitis-related findings correlated with bacteriological findings in the CSF, including gingipain activity? In that case, does the correlation depend on the time interval between the periodontal assessments and the CSF sample? Are P. gingivalis-related findings more common or more pronounced than findings related to other periodontal pathogens in any of these potential relationships? Are P. gingivalis-related findings and other bacteriological findings in the CSF more common or more elevated in participants with AD, as compared to participants with non-Alzheimer dementias? Are P. gingivalis-related findings and other bacteriological findings in the CSF correlated with AD-markers in the CSF, such as β-amyloid, tau and phospho-tau? Participants The study is based on a cohort of participants that has been investigated for assumed cognitive impairment at the Memory Clinic (Minnesmottagningen), Department of Geriatric Medicine, Örebro University Hospital. The clinical examination includes cognitive tests, brain imaging, etc. A diagnosis of dementia or mild cognitive impairment may be given, but other cases will not receive any of these diagnoses. As a part of these investigations, a lumbar puncture is usually performed to analyze AD-markers in the cerebrospinal fluid (CSF). Approximately 200 lumbar punctures are performed annually, and an aliquot of each sample (1 - 2 mL) is routinely stored in a biobank for 5 years or longer. To the investigators knowledge, at least 300 samples are stored. A retrospective analysis of these CSF samples will form the basis for the investigators biochemical investigations. From these approximately 300 cases we will select 120 participants to include in our study. Those that received a diagnosis of dementia will be the case group, those that did not fulfil dementia criteria (around 25 %) will serve as a control group. Participants with the most complete available clinical data until we reach 120 inclusions will be included. Data collection Cognitive function and existing CSF data The medical records from Minnesmottagningen include results from cognitive tests, e.g. MMSE, Clock Drawing Test, Trail Making Tests, etc. These will be retrieved and registered. The diagnoses given at Minnesmottagningen, i.e. dementia (if available, also the etiological type of dementia), minor cognitive impairment, other or no diagnosis, will be documented. The documented results of CSF-analyses of AD-markers, such as β-amyloid, tau and phospho-tau will be retrieved and registered. Risk factors for Alzheimer disease and periodontitis From the participants' medical records, information on known risk factors for AD and periodontitis will be collected, notably hypertension, hyperlipidemia, diabetes mellitus, smoking, alcohol consumption, overweight and obesity, coronary heart disease. Periodontal evaluation Dental records, including radiographs from the participants' dentists up to 15 years back will be searched for and reviewed. Periodontal status will be assessed by research dentists based on radiographs and clinical examinations extracted from the study participants' dental records. CSF analyses These analyses are viewed as explorative. Therefore, the investigators plan interim evaluations after the first 30 results (for each analysis), to estimate the feasibility of continued analysis. Some of the analyses will be performed at laboratories available to the research group, other analyses will be sent to established research laboratories. Analyses will include: Bacterial DNA from selected species by Polymerase Chain Reaction (PCR). Gingipain analyses with Enzyme-Linked Immunosorbent Assay (ELISA) and with a specific sensor. Antibodies against selected bacteria with ELISA. Cytokines, chemokines and growth factors with ELISA / Multiplex. The study is planned to include e.g Aggregatibacter actinomycetemcomitans, Tannerella forsythia and Treponema denticola, however, focusing on P. gingivalis. Statistical considerations The power analysis is based on a study from 2019. In CSF from 10 individuals with AD, P. gingivalis DNA was detected in seven, but no control CSFs were included. However, in their post-mortem brain parenchyma analyses, P. gingivalis toxins were present in 91-96 % of AD brains and 39-52 % of control brains. The investigators may envisage 70 % positive CSF findings in dementia participants versus 30 % in controls based on this. For 80 % statistical power and α set at 0.05, the investigators would need a minimum sample size of 61 patients. Due to the explorative nature of the investigators study and a number of uncertainties concerning these calculations, the investigators want to include 120 patients in the study, with an interim evaluation of the CSF analyses after 30 analyses. Statistical analyzes will be carried out in the computer program Statistical Package for the Social Sciences (SPSS) and will include established standard analyzes, e.g. T-tests, Mann-Whitney tests, Pearson and Spearman correlations, logistic and multivariate regressions. Significance and scientific novelty The results from this study could provide support for the theory that periodontitis and specific bacteria, implicated in the development of periodontitis, are involved in the pathogenesis and development of dementia. Clarifying the disease mechanisms of Alzheimer's disease and other types of dementia is an important step toward finding more efficient strategies to prevent and treat these diseases in the future. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |